- Home
- GLTO vs CLEU Comparison
GLTO vs CLEU Comparison
Compare GLTO & CLEU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- CLEU
- Stock Information
- Founded
- GLTO 2011
- CLEU 2011
- Country
- GLTO Denmark
- CLEU China
- Employees
- GLTO N/A
- CLEU N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- CLEU Other Consumer Services
- Sector
- GLTO Health Care
- CLEU Real Estate
- Exchange
- GLTO Nasdaq
- CLEU Nasdaq
- Market Cap
- GLTO 4.0M
- CLEU 4.6M
- IPO Year
- GLTO 2020
- CLEU 2020
- Fundamental
- Price
- GLTO $3.29
- CLEU $0.08
- Analyst Decision
- GLTO Buy
- CLEU
- Analyst Count
- GLTO 1
- CLEU 0
- Target Price
- GLTO $10.00
- CLEU N/A
- AVG Volume (30 Days)
- GLTO 86.6K
- CLEU 131.3K
- Earning Date
- GLTO 05-08-2025
- CLEU 01-01-0001
- Dividend Yield
- GLTO N/A
- CLEU N/A
- EPS Growth
- GLTO N/A
- CLEU N/A
- EPS
- GLTO N/A
- CLEU N/A
- Revenue
- GLTO N/A
- CLEU $2,413,409.00
- Revenue This Year
- GLTO N/A
- CLEU N/A
- Revenue Next Year
- GLTO N/A
- CLEU N/A
- P/E Ratio
- GLTO N/A
- CLEU N/A
- Revenue Growth
- GLTO N/A
- CLEU N/A
- 52 Week Low
- GLTO $2.01
- CLEU $0.66
- 52 Week High
- GLTO $16.07
- CLEU $4,164.00
- Technical
- Relative Strength Index (RSI)
- GLTO 59.33
- CLEU 18.16
- Support Level
- GLTO $3.05
- CLEU $0.87
- Resistance Level
- GLTO $3.49
- CLEU $1.11
- Average True Range (ATR)
- GLTO 0.26
- CLEU 0.19
- MACD
- GLTO 0.04
- CLEU -0.13
- Stochastic Oscillator
- GLTO 75.76
- CLEU 0.36
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About CLEU China Liberal Education Holdings Limited
China Liberal Education Holdings Ltd is an educational service provider operating in China. The company's operating segment includes Sino-foreign Jointly Managed Academic Programs, textbooks and course material sales, Overseas Study Consulting Services, Technological Consulting Services for Smart Campus Solutions and Tailored Job Readiness Training Services. Geographically, it derives revenue from China.